For people with narcolepsy type 1, treatment has long been a patchwork: stimulants to hold off daytime sleepiness, sodium oxybate to soften cataplexy, antidepressants for hallucinations and sleep paralysis. None of them touched the root of the problem. On Aug. 5, 2026, that changed. The U.S. Food and Drug Administration approved Orzeyful (oveporexton), an oral Takeda medication, for adults with narcolepsy type 1. The agency called it the first treatment cleared for the whole disorder and the first whose mode of action is direct restoration of the orexin signal the disease has lost.
The condition affects roughly one person in 2,000, runs a lifelong course, and is often missed for years. Its defining pathology is the loss of neurons that produce orexin, a chemical messenger discovered in 1998 that regulates wakefulness, sleep, and muscle tone. When that signal is missing, staying alert becomes a constant struggle and the boundary between sleeping and waking blurs. The result is persistent daytime drowsiness; cataplexy, in which strong emotion such as laughter briefly paralyzes the muscles; sleep paralysis; hallucinations at the borders of sleep; and broken nighttime sleep. These symptoms can get in the way of eating, walking, and driving. Before this approval, the FDA pointed out, no drug had ever been cleared for the disorder as one condition, and none acted on the orexin system. Older drugs act downstream of the cause: wake-promoting agents such as stimulants, modafinil, and pitolisant hold off sleepiness; sodium oxybate dampens cataplexy and overnight sleep disruption; antidepressants blunt REM-related symptoms.
Orzeyful takes a different approach. It belongs to a new class of medicine: an oral OX2R agonist that switches on the very receptor the brain’s own orexin is meant to engage, rebuilding the absent signal instead of managing its fallout. It is taken as a tablet twice daily.
The evidence comes from two randomized, double-blinded, placebo-controlled 12-week trials, FirstLight and RadiantLight (NCT06470828 and NCT06505031), which together enrolled 273 adults across 19 countries. At the 2 mg dose, the drug beat placebo on the Maintenance of Wakefulness Test, an objective readout of how long a person can remain awake, and cut daytime sleepiness substantially. Cataplexy episodes fell significantly, and patients improved across the remaining symptom spectrum, including sleep paralysis, hallucinations, and broken nighttime sleep. The trials also logged improvements in daily function and cognition, fewer hallucinations and sleep-paralysis episodes, and REM architecture drifting toward a healthier pattern. Among those who completed the trials, more than 95% chose to continue into the long-term extension, and few stopped treatment because of side effects.
The safety profile matches what activating the wakefulness system would predict. Side effects cluster where a drug that boosts arousal would be expected to bite: trouble sleeping, more frequent urination with a sense of urgency, and extra saliva. It must not be combined with strong CYP3A inhibitors, and patients are urged to list every medication they take for their clinicians. Safety and effectiveness have not been established in anyone younger than 18.
Steps remain before Orzeyful reaches patients. The drug received FDA Breakthrough Therapy designation and Priority Review, reflecting early evidence of substantial improvement for a serious condition. The FDA also recommended placing the drug under Controlled Substances Act scheduling, so lawful marketing has to wait for the Drug Enforcement Administration’s scheduling decision, expected within 90 days. Takeda said the drug will then be made available to U.S. health care providers and adults living with narcolepsy type 1 through a specialty pharmacy.
For a field that has treated narcolepsy type 1 symptom by symptom for decades, the approval marks a shift in direction. Orzeyful stands alone as the first treatment to go after the disease’s molecular core, the missing orexin signal, rather than the symptoms it leaves behind. Whether restoring that signal can meaningfully change the daily lives of people with the disorder will now be tested in the clinic, one prescription at a time.
Source
- American Academy of Sleep Medicine, “FDA Approves Orzeyful for Narcolepsy Type 1 in Adults,” Aug. 6, 2026, https://aasm.org
- U.S. Food and Drug Administration, “FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms,” Aug. 5, 2026, https://www.fda.gov
- Takeda, “U.S. FDA Approves Takeda’s ORZEYFUL (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1,” Aug. 5, 2026, https://www.takeda.com